Floatz logo

Avzo-103

Solid Tumor Cancer

Avenzo Therapeutics, Inc.Phase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

42 Active assets in the Solid Tumor Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
Sarcoma Oncology Research Center, LLC
Phase 2CCC
Zofran
GlaxoSmithKline
Phase 3CCC
Casopitant
GlaxoSmithKline
Phase 3CCC
DEXAMETHASONE
GlaxoSmithKline
Phase 3CCC
Pembrolizumab
GV20 Therapeutics
Phase 1/2CCC

View all 50 →

Same molecule, other indications

Avzo-103 is also rated in:

Locally AdvancedDormant
CC
Indicative ·
47 / 100
View asset →
urothelial carcinomaDormant
CC
Indicative ·
45 / 100
View asset →
metastatic malignant neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →